|
|
Post by uvula on Nov 1, 2022 13:01:40 GMT -5
Today's news is good. But you have to remember that the "up to 100 million" being thrown around in 2016 was never a real number. Rls was not really a company and mnkd was on life support. If a company tells you they will pay you up to a billion dollars it doesn't mean much of anything.
|
|
|
|
Post by peppy on Nov 1, 2022 13:12:08 GMT -5
Today's news is good. But you have to remember that the "up to 100 million" being thrown around in 2016 was never a real number. Rls was not really a company and mnkd was on life support. If a company tells you they will pay you up to a billion dollars it doesn't mean much of anything. As near as I can tell, the scuttle butt is RLS wants FDA approval. A epilepsy drug that some families have fought for, moved locations to obtain because it works for their children FDA approved using technosphere. Epilepsy. There are YouTube videos. |
|
|
|
Post by Thundersnow on Nov 1, 2022 14:38:35 GMT -5
I’m going to guess the next milestone payment is contingent on FDA approval or perhaps even a successful Phase 3 clinical trial, but seems unlikely considering the way it’s been unfolding heretofore. I suspect we will see a major BP partnership announcement from Receptor in the near future. If Receptor is successful in gaining FDA approval, and ultimately commercialization of their two products utilizing MannKind’s revolutionary Technosphere dry powder drug delivery inhalation platform, MannKind will be receiving two new royalties streams. 😎 Dude - RLS has no money so getting a milestone payment will not happen unless they sign a partner with deep pockets. Even then it will be after more trials which will take a couple more years and royalties are way down the road. |
|
|
|
Post by Thundersnow on Nov 1, 2022 14:41:09 GMT -5
Yeah I was curious why you specified “in the near future.” Because RLS 103 phase 1 for the acute anxiety in social anxiety disorder wraps up early next year. Receptor may be looking for a partner to take it through Phase 3 and ultimately commercialization (assuming Receptor is not planning on going solo). Hope this helps clear things up for you. The best outcome would be for MNKD to buyout RLS for $100 - $150M in a couple of years and own the 2 drugs. By then MNKD will be getting nice royalties from UTHR and can afford a purchase with DEBT. |
|
|
|
Post by cretin11 on Nov 1, 2022 14:46:55 GMT -5
Yeah I was curious why you specified “in the near future.” Because RLS 103 phase 1 for the acute anxiety in social anxiety disorder wraps up early next year. Receptor may be looking for a partner to take it through Phase 3 and ultimately commercialization (assuming Receptor is not planning on going solo). Hope this helps clear things up for you. Thanks, that does help explain your prediction. Hope you're right, but I strongly agree with Thundersnow there won't be a BP partner for this "in the near future." |
|
|
|
Post by mango on Nov 1, 2022 14:56:44 GMT -5
Because RLS 103 phase 1 for the acute anxiety in social anxiety disorder wraps up early next year. Receptor may be looking for a partner to take it through Phase 3 and ultimately commercialization (assuming Receptor is not planning on going solo). Hope this helps clear things up for you. Thanks, that does help explain your prediction. Hope you're right, but I strongly agree with Thundersnow there won't be a BP partner for this "in the near future." I never made a prediction. What part of my text are you confused about? |
|
|
|
Post by cretin11 on Nov 1, 2022 15:03:06 GMT -5
Thanks, that does help explain your prediction. Hope you're right, but I strongly agree with Thundersnow there won't be a BP partner for this "in the near future." I never made a prediction. What part of my text are you confused about? "I suspect we will see a major BP partnership announcement from Receptor in the near future." mango, 11/1/2022, ProBoards |
|
|
|
Post by mango on Nov 1, 2022 15:23:03 GMT -5
I never made a prediction. What part of my text are you confused about? "I suspect we will see a major BP partnership announcement from Receptor in the near future." mango, 11/1/2022, ProBoards To suspect something is not the same as to predict something. |
|
|
|
Post by peppy on Nov 1, 2022 15:40:52 GMT -5
I’m going to guess the next milestone payment is contingent on FDA approval or perhaps even a successful Phase 3 clinical trial, but seems unlikely considering the way it’s been unfolding heretofore. I suspect we will see a major BP partnership announcement from Receptor in the near future. If Receptor is successful in gaining FDA approval, and ultimately commercialization of their two products utilizing MannKind’s revolutionary Technosphere dry powder drug delivery inhalation platform, MannKind will be receiving two new royalties streams. 😎 Dude - RLS has no money so getting a milestone payment will not happen unless they sign a partner with deep pockets. Even then it will be after more trials which will take a couple more years and royalties are way down the road. RLS raises money from time to time. In the blink of an eye. |
|
|
|
Post by anderson on Nov 1, 2022 16:47:14 GMT -5
Dude - RLS has no money so getting a milestone payment will not happen unless they sign a partner with deep pockets. Even then it will be after more trials which will take a couple more years and royalties are way down the road. RLS raises money from time to time. In the blink of an eye. Would FDA approval for epilepsy in children qualify for a FDA Priority voucher? Those things are worth about $100 mil. |
|
|
|
Post by longliner on Jan 17, 2023 20:05:04 GMT -5
|
|
|
|
Post by Clement on Jan 18, 2023 9:13:11 GMT -5
|
|
